Katedra za farmaciju

View Statistics Email Alert RSS Feed
Organization name
Katedra za farmaciju
Parent OrgUnit
City
Novi Sad
Country
Serbia

OrgUnit's Researchers publications
(Dept/Workgroup Publication)

Refined By:
Type:  Other

Results 1-20 of 28 (Search time: 0.004 seconds).

Issue DateTitleAuthor(s)
11-Jan-2019“15th International Phytotechnologies Conference” Novi Sad, Serbia, October 1–5, 2018Pilipović, Ana ; Zalesny R.
21-Sep-2019Adiponectin: a therapeutic target in the antiphospholipid syndrome?Mirjana Bećarević ; Božana Nikolić ; Svetlana Ignjatović
31-Dec-2012Anti-oxidant therapy in non-alcoholic fatty liver disease: The role of silymarinAbenavoli L.; Milić, Nataša ; Capasso F.
41-Jul-2017Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome—Biomarkers of the Disease and BiopharmaceuticalsMirjana Bećarević 
51-Jan-2015Applications of anti/prooxidant fullerenes in nanomedicine along with fullerenes influence on the immune systemPetrović, Danijela; Seke, Mariana; Srđenović, Branislava ; Đorđević, Aleksandar 
61-Dec-2019Author Correction: Increase of isoflavones in the aglycone form in soybeans by targeted crossings of cultivated breeding material (Scientific Reports, (2019), 9, 1, (10341), 10.1038/s41598-019-46817-1)Jegor Miladinović; Vuk Đorđević; Svetlana Balešević-Tubić; Kristina Petrović; Marina Ćeranić; Jelena Helen Hogervorst ; Mira Mikulić ; Dragana Miladinović
71-Jan-2017Bile acids as novel pharmacological agents: The interplay between gene polymorphisms, epigenetic factors and drug responseNebojša Pavlović ; Bojan Stanimirov ; Momir Mikov 
81-Feb-2013Dietary Intervention in Non-Alcoholic Fatty Liver DiseaseAbenavoli L.; Milić, Nataša 
91-Jan-2019DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal ImpairmentMikov, Momir ; Pavlović, Nebojša ; Stanimirov, Bojan ; Đanić, Maja ; Goločorbin-Kon, Svetlana ; Stankov, Karmen ; Al-Salami H.
101-Apr-2015Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver diseaseAbenavoli L.; Greco M.; Nazionale I.; Peta V.; Milić, Nataša ; Accattato F.; Foti D.; Gulletta E.; Luzza F.
111-Jan-2016Ganoderma: Insights into anticancer effectsKladar, Nebojša ; Gavarić, Neda ; Božin, Biljana 
122-Sep-2017Gut microbiota changes and chronic hepatitis C virus infectionPreveden, Andrej; Scarpellini E.; Milić, Nataša ; Luzza F.; Abenavoli L.
139-Aug-2012Hydrophobicity and self-association of bile acids with a special emphasis on oxo derivatives of 5-β cholanic acidPoša, Mihalj 
141-Nov-2016The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndromeBećarević, Mirjana 
151-Oct-2012An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and SwedenPavlović, Nebojša ; Stanimirov, Bojan ; Stojančević M.; Paut-Kusturica M.; Stoimenova A.; Goločorbin-Kon, Svetlana ; Mikov, Momir 
161-Mar-2013Liver steatosis in celiac disease: The open doorAbenavoli L.; Luigiano C.; Larussa T.; Milić, Nataša ; De Lorenzo A.; Stelitano L.; Morace C.; Consolo P.; Miraglia S.; Fagoonee S.; Virgilio C.; Luzza F.; Pellicano R.
171-Jan-2014Low 25-hydroxyvitamin D3 serum levels and non-alcoholic fatty liver diseaseAbenavoli L.; Milić, Nataša ; Luigiano C.
181-Nov-2018Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseasesAbenavoli L.; Izzo A.; Milić, Nataša ; Cicala C.; Santini A.; Capasso R.
191-Mar-2011Milk thistle for treatment of nonalcoholic fatty liver diseaseAbenavoli L.; Aviello G.; Capasso R.; Milić, Nataša ; Capasso F.
201-Oct-2010Milk thistle in liver diseases: Past, present, futureAbenavoli L.; Capasso R.; Milić, Nataša ; Capasso F.